var data={"title":"Metoclopramide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metoclopramide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metoclopramide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metoclopramide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=metoclopramide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metoclopramide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8117624\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Tardive dyskinesia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. There is no known treatment for tardive dyskinesia. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. Discontinue metoclopramide in patients who develop signs or symptoms of tardive dyskinesia. In some patients, symptoms lessen or resolve after metoclopramide is stopped. Avoid treatment with metoclopramide for longer than 12 weeks because of the increased risk of developing tardive dyskinesia with longer-term use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195600\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Metozolv ODT [DSC];</li>\n      <li>Reglan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195601\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Metoclopramide Hydrochloride Injection;</li>\n      <li>Metoclopramide Omega;</li>\n      <li>Metonia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195655\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiemetic;</li>\n      <li>\n        Gastrointestinal Agent, Prokinetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195605\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic gastroparesis: Note:</b> American Diabetes Association guidelines state that use should be reserved for severe cases that are unresponsive to other therapies; when used, duration should be &le;5 days (ADA 2018).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (acute and recurrent): Manufacturer&rsquo;s labeling: 10 mg 4 times daily for 2 to 8 weeks (maximum: 40 mg/day). Do not treat for &gt;12 weeks. <b>Note:</b> 5 mg 4 times daily (maximum: 20 mg/day) is recommended for poor metabolizers of CYP2D6.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV (for severe symptoms): 10 mg over 1 to 2 minutes; 10 days of IV therapy may be necessary before symptoms are controlled to allow transition to oral administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroparesis management, regardless of etiology (off-label use):</b> American College of Gastroenterology Guidelines: Oral: Initial: 5 mg 3 times daily before meals. Dosage range: 5 to 10 mg 2 to 3 times daily before meals (maximum: 40 mg daily). Liquid formulation is preferred (to increase absorption) and the use of drug holidays or dose reductions (eg, 5 mg before the two main meals of the day) is also recommended when clinically possible (Camilleri 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal reflux:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous dosing: 10 to 15 mg 4 times daily for 4 to 12 weeks (maximum: 60 mg/day). <b>Note:</b> 5 mg 4 times daily or 10 mg 3 times daily (maximum: 30 mg/day) is recommended for poor metabolizers of CYP2D6.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent dosing: Single doses up to 20 mg (prior to provoking situation) if symptoms occur only intermittently or at specific times of the day. Do not treat &gt;12 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of nausea and vomiting associated with emetogenic chemotherapy:</b> IV: <b>Note: </b>Pretreatment with diphenhydramine will decrease risk of extrapyramidal reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Highly emetogenic: Initial dose: 2 mg/kg over 15 minutes 30 minutes before chemotherapy; repeat every 2 hours for 2 doses, then every 3 hours for 3 doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Less emetogenic: Initial dose: 1 mg/kg over 15 minutes 30 minutes before chemotherapy; repeat every 2 hours for 2 doses, then every 3 hours for 3 doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed-emesis prophylaxis (off-label):</i> Oral: 20 to 40 mg (or 0.5 mg/kg/dose) 2 to 4 times daily for 3 to 4 days in combination with dexamethasone (ASCO guidelines (Kris 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Refractory or intolerant to antiemetics with a higher therapeutic index (off-label) (Hesketh 2008): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1 to 2 mg/kg/dose before chemotherapy and repeat 2 hours after chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 0.5 mg/kg every 6 hours on days 2 to 4.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of postoperative nausea and vomiting:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV (off-label route): Usual dose: 10 mg near end of surgery; some patients may require 20 mg. <b>Note:</b> Guidelines discourage use of 10 mg metoclopramide due to lack of effectiveness (Gan 2007); comparative study indicates higher dose (20 mg) may be efficacious (Quaynor 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (off-label route): 20 mg orally 2 hours prior to anesthesia has been recommended (Metonia Canadian product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Radiological exam:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (off-label route): 20 mg as a single dose 5 to 10 minutes prior to exam (Metonia Canadian product labeling 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Small bowel intubation (postpyloric feeding tube placement):</b> IV: 10 mg as a single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastric bezoars (off-label use): </b>Oral, IV: 5 to 10 mg 3 to 4 times daily until resolution (Gaya 2002; Winkler 1983). To prevent further bezoar formation, metoclopramide was continued for up to 16 months in one study (Winkler 1983). Additional data may be necessary to further define the role of metoclopramide in the treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous infusion:</i> IV: 40 mg administered over 24 hours for 3 days; may repeat if bezoar is not cleared (Delpre 1984).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hiccups (off-label use): Note: </b>Additional data may be necessary to further define the role of metoclopramide in the prevention and treatment of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.17 mg/kg as a single dose starting the day of or 1 day before anticipated hiccup-precipitating event (Stav 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 10 mg every 6 to 8 hours starting the day of or 1 day before anticipated hiccup-precipitating event (Baethge 1986; Cersosimo 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, IM: 5 to 10 mg every 8 hours (Madanagopolan 1975; Middleton 1973). Therapy may begin with parenteral dosing and transition to oral dosing (10 mg orally every 6 to 8 hours) when hiccups are controlled. Treatment usually continues until metoclopramide can be withdrawn without provoking a recurrence (Friedman 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 10 mg every 6 to 8 hours (Madanagopolan 1975; Middleton 1973).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine (acute) (off-label use): Note: </b>The IV route is preferred by the American Headache Society (AHS [Orr 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 10 to 20 mg as a single dose (EFNS [Evers 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, SubQ: 10 mg as a single dose (EFNS [Evers 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 to 20 mg as a single dose (AHS [Orr 2016]; EFNS [Evers 2009]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of radiation therapy-induced nausea and vomiting (minimal emetic risk) (off-label use):</b> Oral: 20 mg as rescue therapy; if rescue therapy is used, then administer prior to each fraction until the end of radiation therapy (Basch 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of nausea and vomiting in advanced cancer </b>\n      <b>(off-label use): </b>Oral, IV, IM, SubQ (off-label route): 5 mg four times a day (30 minutes prior to meals and at bedtime) (Protus 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CYP2D6 inhibitors (eg, bupropion, fluoxetine, quinidine, paroxetine): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Diabetic gastroparesis: 5 mg 4 times daily (maximum: 20 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastroesophageal reflux: 5 mg 4 times daily or 10 mg 3 times daily (maximum: 30 mg/day)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195630\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=metoclopramide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metoclopramide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Small bowel intubation (postpyloric feeding tube placement):</b> Children and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;6 years: 0.1 mg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">6 to 14 years: 2.5 to 5 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;14 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-associated nausea and vomiting (off-label use):</b> Children and Adolescents: Moderately emetogenic chemotherapy (patients who cannot receive corticosteroids): IV: 1 mg/kg prior to chemotherapy, followed by Oral: 0.0375 mg/kg every 6 hours; regimen also includes ondansetron or granisetron; coadministration of diphenhydramine or benztropine is recommended to prevent metoclopramide-induced adverse effects (Dupuis 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195606\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Initial: Dose at the lower end of the recommended range (may require only 5 mg/dose) and use the lowest effective dose. Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195607\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;40 mL/minute<b>: </b>There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;40 mL/minute: Initial: Administer ~50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetic gastroparesis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt; 60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &le;60 mL/minute: 5 mg 4 times daily (maximum: 20 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD: 5 mg twice daily (maximum: 10 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis and continuous ambulatory peritoneal dialysis: 5 mg twice daily (maximum: 10 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt; 60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &le;60 mL/minute: 5 mg 4 times daily or 10 mg 3 times daily (maximum: 30 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD: 5 mg 4 times daily or 10 mg twice daily (maximum: 20 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis and continuous ambulatory peritoneal dialysis: 5 mg 4 times daily or 10 mg twice daily (maximum: 20 mg/day).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210018\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV</b>: There are no dosage adjustments provided in the manufacturer's labeling. However, metoclopramide has been used safely in patients with advanced liver disease with normal renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetic gastroparesis</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate or severe impairment (Child-Pugh class B or C): 5 mg 4 times daily (maximum: 20 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate or severe impairment (Child-Pugh class B or C): 5 mg 4 times daily or 10 mg 3 times daily (maximum: 30 mg/day).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195570\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (10 mL, 473 mL); 10 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reglan: 5 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reglan: 10 mg [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metozolv ODT: 5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195554\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8083407\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metoclopramide oral solution: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM244086.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68UB3sXUE3glQjEZuI58rBVw==&amp;TOPIC_ID=9642\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM244086.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metozolv ODT: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM187064.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQo4kAbL5TYxyavRm7IY9l4Q==&amp;TOPIC_ID=9642\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM187064.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reglan injection: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM176362.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQN7r4+OcDEcv6bJLefhtiDA==&amp;TOPIC_ID=9642\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM176362.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reglan tablet: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM235574.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68aJQyg8gZ9p8gvETRU3w7hQ==&amp;TOPIC_ID=9642\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM235574.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195574\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: May be given IM, direct IV push, short infusion (at least 15 minutes), or continuous infusion; lower doses (&le;10 mg) of metoclopramide can be given IV push undiluted over 1 to 2 minutes; higher doses (&gt;10 mg) to be diluted in 50 mL of compatible solution (preferably NS) and given IVPB over at least 15 minutes. <b>Note:</b> Rapid IV administration may be associated with a transient (but intense) feeling of anxiety and restlessness, followed by drowsiness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets and oral solution: Administer 30 minutes prior to meals and at bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orally disintegrating tablets: Administer on an empty stomach at least 30 minutes prior to food and at bedtime (do not repeat if inadvertently taken with food). Do not remove from packaging until time of administration. If tablet breaks or crumbles while handling, discard and remove new tablet. Using dry hands, place tablet on tongue and allow to dissolve (disintegrates within ~1 minute [range: 10 seconds to 14 minutes]). Swallow with saliva (formulation is designed to be taken without liquids).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subcutaneous administration (off-label route) has been reported, either as an intermittent bolus injection or as continuous infusion (Bruera 1996; McCallum 1991).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195573\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Injection:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetic gastroparesis (diabetic gastric stasis):</b> Relief of symptoms associated with acute and recurrent diabetic gastric stasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy:</b> Prophylaxis of vomiting associated with emetogenic cancer chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of postoperative nausea and vomiting:</b> Prophylaxis of postoperative nausea and vomiting in circumstances where nasogastric suction is undesirable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Radiological examination:</b> To stimulate gastric emptying and intestinal transit of barium when delayed emptying interferes with radiological examination of the stomach and/or small intestine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Small bowel intubation:</b> To facilitate small bowel intubation in adults and pediatrics in whom the tube does not pass the pylorus with conventional maneuvers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Oral:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetic gastroparesis:</b> Relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux:</b> Short-term (4 to 12 weeks) treatment in adults with documented symptomatic GERD who fail to respond to conventional therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469403\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Gastric bezoars; Gastroparesis (regardless of etiology); Hiccups; Migraine (acute); Prevention of chemotherapy-associated nausea and vomiting (pediatrics); Prevention of radiation therapy-induced nausea and vomiting (minimal emetic risk); Treatment of nausea and vomiting in advanced cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195664\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Metoclopramide may be confused with metOLazone, metoprolol, metroNIDAZOLE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Reglan may be confused with Megace, Regonol, Renagel, Regitine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Metoclopramide is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless used for the treatment of gastroparesis) due to its potential for causing extrapyramidal effects, including tardive dyskinesia; these risks may be increased in frail older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195561\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrioventricular block, bradycardia, cardiac failure, flushing (following high IV doses), hypertension, hypotension, supraventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drowsiness (~10% to 70%; dose related), dystonic reaction (&lt;1% to 25%; dose and age related), lassitude (~10%), restlessness (~10%), fatigue (2% to 10%), headache (4% to 5%), dizziness (1% to 4%), somnolence (2% to 3%), akathisia, confusion, depression, drug-induced Parkinson's disease, hallucination (rare), insomnia, neuroleptic malignant syndrome (rare), seizure, suicidal ideation, tardive dyskinesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, fluid retention, galactorrhea, gynecomastia, hyperprolactinemia, porphyria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea (4% to 6%), vomiting (1% to 2%), diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, urinary frequency, urinary incontinence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, leukopenia, methemoglobinemia, neutropenia, sulfhemoglobinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema (rare), hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Laryngospasm (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, laryngeal edema (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195578\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, laryngeal and glossal angioedema, bronchospasm) to metoclopramide or any component of the formulation; situations where stimulation of gastrointestinal (GI) motility may be dangerous, including mechanical GI obstruction, perforation, or hemorrhage (except when used prior to endoscopy for evaluation of acute upper GI bleeding [Barkun 2010]); pheochromocytoma or other catecholamine-releasing paragangliomas; seizure disorder (eg, epilepsy); history of tardive dyskinesia or dystonic reaction to metoclopramide; concomitant use with other agents likely to increase extrapyramidal reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Infants &lt;1 year of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195558\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Depression has occurred (in patients with and without a history of depression); symptoms have included suicidal ideation and suicide; avoid use in patients with a history of depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, generally manifested as acute dystonic reactions within the initial 24 to 48 hours of use at the usual adult dose (30 to 40 mg/day). Risk of these reactions is increased at higher than recommended doses, and in patients &lt;30 years of age. Symptoms may include involuntary limb movements, facial grimacing, torticollis, oculogyric crisis, rhythmic tongue protrusion, bulbar type speech, trismus, or dystonic reactions resembling tetanus. May also rarely present as stridor and dyspnea (may be due to laryngospasm). Dystonic symptoms may be managed with IM diphenhydramine or benztropine. Pseudoparkinsonism (eg, bradykinesia, tremor, cogwheel rigidity, mask-like facies) may also occur (usually within first 6 months of therapy but also after longer periods) and is generally reversible within 2 to 3 months following discontinuation. Motor restlessness (eg, anxiety, agitation, jitteriness, insomnia) may occur; if symptoms resolve, consider restarting at a lower dosage. Avoid metoclopramide in patients receiving other drugs that are likely to cause EPS (eg, antipsychotics).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: Metoclopramide elevates prolactin levels. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported. Hyperprolactinemia may potentially stimulate prolactin-dependent breast cancer. However, some clinical studies and epidemiology studies have not shown an association between administration of dopamine D<sub>2</sub> receptor antagonists and tumorigenesis in humans.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: May elevate blood pressure; avoid use in patients with hypertension (IV administration was shown to release catecholamines). There are reports of hypertensive crises in patients with undiagnosed pheochromocytoma; use is contraindicated in patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Discontinue therapy in any patient with a rapid rise in blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome: Use may be associated with neuroleptic malignant syndrome (NMS); may be fatal. Monitor for manifestations of NMS, which include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac arrhythmias); additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure. Discontinue immediately if signs/symptoms of NMS appear and begin intensive symptomatic management and monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: Metoclopramide has been known to cause sinus arrest (usually with rapid IV administration or higher doses) (Bentsen 2002; Malkoff 1995). The torsadogenic potential for metoclopramide is considered to be low (Claassen 2005). Based on case reports, however, metoclopramide may cause QT prolongation and torsades de pointes in certain individuals (eg, heart failure patients with renal impairment) (Siddique 2009). There is data in healthy male volunteers to show that metoclopramide actually shortens the QT interval while at the same time increasing QT variance (Ellidokuz 2003). No human data other than case reports, however, has demonstrated a consistent QT prolonging effect with metoclopramide nor is there any substantiated evidence to show a direct association with the development of torsades de pointes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tardive dyskinesia: <b>[US Boxed Warning]: May cause tardive dyskinesia, a serious movement disorder that is often irreversible with no known treatment; the risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. Discontinue metoclopramide in patients who develop signs/symptoms of tardive dyskinesia; in some patients, symptoms may lessen or resolve after metoclopramide is stopped. Avoid treatment with metoclopramide for longer than 12 weeks because of the increased risk of developing tardive dyskinesia with longer-term use.</b> Avoid metoclopramide in patients receiving other drugs that are likely to cause tardive dyskinesia (eg, antipsychotics). Tardive dyskinesia is characterized by disfiguring involuntary movements of the face, tongue, and sometimes of the trunk and/or extremities; movements may be choreoathetotic in appearance. Metoclopramide may mask underlying tardive disease by suppressing or partially suppressing tardive dyskinesia signs; the effect of this symptomatic suppression upon the long-term course of tardive dyskinesia is unknown. The risk of developing tardive dyskinesia is increased in the elderly, especially elderly women, and diabetics, although it is not possible to predict which patients will develop tardive dyskinesia. Discontinue metoclopramide immediately in patients who develop signs/symptoms of tardive dyskinesia. There is no known effective treatment for established cases of tardive dyskinesia, although in some patients, tardive dyskinesia may remit (partially or completely) within several weeks to months after metoclopramide is withdrawn.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure and concomitant renal impairment; may be at risk for development of QT prolongation and torsades de pointes (Siddique 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edematous conditions: Use with caution in patients who are at risk of fluid overload (HF, cirrhosis). Metoclopramide causes a transient increase in serum aldosterone and increases the risk for fluid retention and volume overload. Discontinue if adverse events or signs/symptoms appear.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with moderate to severe hepatic impairment; risk of adverse reactions may be increased due to increased systemic exposure; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nicotinamide adenine dinucleotide hydrogen (NADH)-cytochrome b5 reductase deficiency: Patients with NADH-cytochrome b5 reductase deficiency are at increased risk of methemoglobinemia and/or sulfhemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Symptoms of Parkinson disease may be exacerbated; avoid use in patients with Parkinson disease and other patients being treated with antiparkinsonian drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment; risk of adverse reactions may be increased due to increased systemic exposure; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical anastomosis/closure: Use with caution following surgical anastomosis/closure; promotility agents may theoretically increase pressure in suture lines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP2D6 poor metabolizers: Elimination of metoclopramide may be slowed possibly increasing the risk of dystonic and other adverse reactions; dosage reduction recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Risk of tardive dyskinesia may be increased in elderly, especially in elderly women.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not recommended for use (oral formulation) due to increased risk of tardive dyskinesia and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates (neonates may have decreased levels of NADH-cytochrome b5 reductase, which increases the risk of methemoglobinemia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195649\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195563\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9642&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Metoclopramide may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Metoclopramide may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atovaquone: Metoclopramide may decrease the serum concentration of Atovaquone.  Management: Consider alternatives to metoclopramide when possible; atovaquone should only be used with metoclopramide if no other antiemetics are available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Metoclopramide may increase the absorption of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deutetrabenazine: May enhance the adverse/toxic effect of Metoclopramide. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the adverse/toxic effect of Metoclopramide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Benzamide Derivatives may enhance the adverse/toxic effect of Levosulpiride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Metoclopramide. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with metyrosine for development of extrapyramidal symptoms.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Metoclopramide may decrease the serum concentration of Posaconazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promethazine: Metoclopramide may enhance the adverse/toxic effect of Promethazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Metoclopramide may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the adverse/toxic effect of Metoclopramide. Specifically, the risk of extrapyramidal adverse reactions  may be increased with this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: Metoclopramide may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.  Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: Metoclopramide may enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors.  Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with serotonin/norepinephrine reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrabenazine: Metoclopramide may enhance the adverse/toxic effect of Tetrabenazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopental: Metoclopramide may enhance the therapeutic effect of Thiopental.  Management: Consider thiopental dose reduction when used concomitantly with metoclopramide. Monitor patient response to treatment closely if using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Metoclopramide may enhance the adverse/toxic effect of Tricyclic Antidepressants.  Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimetazidine: Metoclopramide may enhance the adverse/toxic effect of Trimetazidine. Specifically, the risk of extrapyramidal symptoms may be enhanced. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195566\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195581\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Metoclopramide crosses the placenta and can be detected in cord blood and amniotic fluid (Arvela 1983; Bylsma-Howell 1983). Available evidence suggests safe use during pregnancy (ACOG 2015; Berkovitch 2002; Matok 2009; S&oslash;rensen 2000). Evidence related to the efficacy for the treatment of nausea and vomiting of pregnancy is limited (ACOG 2015; Arsenault 2002); metoclopramide may be used for prophylaxis of nausea and vomiting associated with cesarean delivery (ASA 2016; Smith 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195582\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Metoclopramide is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of metoclopramide is ~4.6% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 0.5 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of metoclopramide was calculated using a milk concentration of 0.1565 mcg/mL, providing an estimated daily infant dose via breast milk of 0.023 mg/kg/day. This milk concentration was obtained following maternal administration of oral metoclopramide 10 mg three times daily. Peak milk concentrations appeared approximately the same time as peak maternal serum concentrations, 2 to 3 hours after the dose. Metoclopramide was also detected in the serum of a breastfeeding infant (Kauppila 1983).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although not commonly reported, transient intestinal discomfort has been noted in two breastfed infants following exposure via breast milk (Zuppa 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Metoclopramide may increase prolactin concentrations and cause galactorrhea and gynecomastia. As such, it has been evaluated as a galactagogue in women with difficulty breastfeeding. Studies examining metoclopramide as a breastfeeding aid have mixed results. Metoclopramide has not been shown to significantly increase milk production, duration of breastfeeding, or infant weight gain when compared to placebo (ABM 2011). In addition, studies that compared breastfeeding education and instruction alone to maternal education plus metoclopramide did not demonstrate a benefit from the addition of metoclopramide (Seema 1997; Sakha 2008). Due to the potential for adverse maternal events, nonpharmacologic measures should be considered prior to the use of medications as galactagogues (ABM 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. When treatment for nausea and vomiting is needed, the WHO recommends metoclopramide be avoided due to insufficient data on long-term side effects to the infant (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195568\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of tardive dyskinesias, extrapyramidal symptoms; signs/symptoms of neuroleptic malignant syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195557\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks dopamine receptors and (when given in higher doses) also blocks serotonin receptors in chemoreceptor trigger zone of the CNS; enhances the response to acetylcholine of tissue in upper GI tract causing enhanced motility and accelerated gastric emptying without stimulating gastric, biliary, or pancreatic secretions; increases lower esophageal sphincter tone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195577\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: 30 to 60 minutes; IV: 1 to 3 minutes; IM: 10 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Therapeutic: 1 to 2 hours, regardless of route </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid, well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>:  Neonates, PMA 31 to 40 weeks: 6.94 L/kg (Kearns 1998); Infants: 4.4 L/kg; Children: 3 L/kg; Adults: ~3.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 80 &plusmn; 15.5% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: Neonates, PMA 31 to 40 weeks: 5.4 hours (Kearns, 1998); Infants: 4.15 hours (range: 2.23 to 10.3 hours) (Kearns 1988); Children: ~4 hours (range: 2 to 12.5 hours); half-life and clearance may be dose-dependent; Adults: 5 to 6 hours (may be dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Neonates, PMA 31 to 40 weeks: 2.45 hours (Kearns, 1998); Infants: 2.2 hours; Adults: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~85%); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195580\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Metoclopramide HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (2 mL): $0.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Metoclopramide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (10 mL): $0.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Metoclopramide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (10): $94.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (10): $94.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Metoclopramide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $32.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $27.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Reglan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $354.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $354.94</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195583\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afipran (NO);</li>\n      <li>Ametic (ZA);</li>\n      <li>Anausin (FR);</li>\n      <li>Balon (TW);</li>\n      <li>Carnotprim (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Ceolat (AT);</li>\n      <li>Cerucal (DE, EE, HU, LV);</li>\n      <li>Clomitene (PH);</li>\n      <li>Clopamon (ZA, ZW);</li>\n      <li>Cloperan (MT);</li>\n      <li>Clopram (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Cynovit (ET);</li>\n      <li>Dibertil (BE, LU);</li>\n      <li>Dirpasid (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>DO-Spertine (ET);</li>\n      <li>Donmet (LK);</li>\n      <li>Elitan (MT, TR, VN);</li>\n      <li>Emeliv (SG);</li>\n      <li>Emperal (DK);</li>\n      <li>Enakur (ID);</li>\n      <li>Enzimar (CO);</li>\n      <li>Fluccil (BR);</li>\n      <li>Gastro-Timelets (LU);</li>\n      <li>Gastrobi S.R. (KR);</li>\n      <li>Gastronerton (DE, LU);</li>\n      <li>Gastrosil (CH, DE, LU, PH);</li>\n      <li>Imperan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PY, SA, SY, TW, YE);</li>\n      <li>Itan (CL);</li>\n      <li>Legir (UY);</li>\n      <li>Macperan (KR);</li>\n      <li>Malon (MY);</li>\n      <li>Manosil (TH);</li>\n      <li>Maril (HK, SG, TH);</li>\n      <li>Maxeron (IN);</li>\n      <li>Maxocol (BD);</li>\n      <li>Maxolon (AE, AU, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GY, IE, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>MCP-Beta Tropfen (DE);</li>\n      <li>MCP-ratiopharm (LU);</li>\n      <li>Meclomid (BD, MX);</li>\n      <li>Meclopram (ET);</li>\n      <li>Meclopstad (VN);</li>\n      <li>Mepamide (TH);</li>\n      <li>Metamide (NZ);</li>\n      <li>Metlazel (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Metoclamid (LU);</li>\n      <li>Metoclopramide-Eurogenerics (LU);</li>\n      <li>Metoclox (EC);</li>\n      <li>Metopram (FI);</li>\n      <li>Metovit (LK);</li>\n      <li>Metsil (PH);</li>\n      <li>Migen (BD);</li>\n      <li>Movain (BD);</li>\n      <li>Movistal (LU);</li>\n      <li>Nausil (TH);</li>\n      <li>Nilatika (ID);</li>\n      <li>Norvom (ID);</li>\n      <li>Nutramid (BD);</li>\n      <li>Opram (ID);</li>\n      <li>Paspertin (HU);</li>\n      <li>Perinorm (ET, IN, LK, RU, ZA);</li>\n      <li>Perone (TW);</li>\n      <li>Pharmyork (GR);</li>\n      <li>Piralen (ID);</li>\n      <li>Plasil (AE, BF, BH, BJ, BR, CI, CO, CR, CY, DO, EG, ET, GH, GM, GN, GT, HN, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, OM, PA, PY, QA, SA, SC, SD, SL, SN, SV, SY, TH, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Polcotec (MX);</li>\n      <li>Pramidin (PL);</li>\n      <li>Pramin (AU, IL, TW);</li>\n      <li>Premosan (AE, BH, ET, KW, QA, SA);</li>\n      <li>Primperan (AE, AT, BE, BF, BH, BJ, CH, CI, CO, CR, CY, CZ, DK, DO, EE, EG, ES, ET, FI, FR, GH, GM, GN, GR, GT, HK, HN, JO, JP, KE, KW, LB, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, PA, PE, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SV, TN, TR, TW, TZ, UG, VE, VN, ZM, ZW);</li>\n      <li>Primperil (AR);</li>\n      <li>Prinparl (JP);</li>\n      <li>Prokinyl (LU);</li>\n      <li>Prowel (TW);</li>\n      <li>Pulin (MY, SG);</li>\n      <li>Regelan (PK);</li>\n      <li>Reglan (BG, HR, IN, SI);</li>\n      <li>Reglomar (PH);</li>\n      <li>Regurg (ET);</li>\n      <li>Reliveran (AR);</li>\n      <li>Remetin (LK);</li>\n      <li>Riamide (AE, QA);</li>\n      <li>Setin (ZA);</li>\n      <li>Sotatic-10 (ID);</li>\n      <li>Tricil (PY);</li>\n      <li>Tserukal (UA);</li>\n      <li>Vertivom (ID);</li>\n      <li>Vitamet (PH);</li>\n      <li>Vomaine (PH);</li>\n      <li>Zudaw (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #9: use of galactogogues in initiating or augmenting the rate of maternal milk secretion (First Revision January 2011). <i>Breastfeed Med</i>. 2011;6(1):41-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/21332371/pubmed\" target=\"_blank\" id=\"21332371\">21332371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetrics and Gynecology (ACOG). Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. <i>Obstet Gynecol</i>. 2015;126(3):e12-e24. doi: 10.1097/AOG.0000000000001048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/26287788/pubmed\" target=\"_blank\" id=\"26287788\">26287788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 10. Microvascular complications and foot care: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018;41(suppl 1):S105-S118. doi: 10.2337/dc18-S010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/29222381/pubmed\" target=\"_blank\" id=\"29222381\">29222381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Society of Anesthesiologists (ASA) Task Force on Obstetric Anesthesia. Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. <i>Anesthesiology</i>. 2016;124(2):270-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/26580836/pubmed\" target=\"_blank\" id=\"26580836\">26580836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arsenault MY, Lane CA, MacKinnon CJ, et al. The management of nausea and vomiting of pregnancy. <i>J Obstet Gynaecol Can</i>. 2002;24(10):817-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/12405123/pubmed\" target=\"_blank\" id=\"12405123\">12405123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arvela P, Jouppila R, Kauppila A, et al. Placental transfer and hormonal effects of metoclopramide. <i>Eur J Clin Pharmacol</i>. 1983;24(3):345-348.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/6407846/pubmed\" target=\"_blank\" id=\"6407846\">6407846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007:116.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3510055\"></a>Baethge BA, Lidsky MD. Intractable hiccups associated with high-dose intravenous methylprednisolone therapy. <i>Ann Intern Med</i>. 1986;104(1):58-59.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20970794\"></a>Barkun AN, Bardou M, Martel M, et al. Prokinetics in acute upper GI bleeding: a meta-analysis. <i>Gastrointest Endosc</i>. 2010;72(6):1138-1145.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update [published correction appears in <i>J Clin Oncol</i>. 2011;32(19):2117]. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bentsen G, Stubhaug A. Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest. <i>Acta Anaesthesiol Scand</i>. 2002;46(7):908-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/12139551/pubmed\" target=\"_blank\" id=\"12139551\">12139551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkovitch M, Mazzota P, Greenberg R, et al. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. <i> Am J Perinatol</i>. 2002;19(6):311-316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/12357422/pubmed\" target=\"_blank\" id=\"12357422\">12357422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bruera E, Seifert L, Watanabe S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. <i>J Pain Symptom Manage</i>. 1996;11(3):147-153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/8851371/pubmed\" target=\"_blank\" id=\"8851371\">8851371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bylsma-Howell M, Riggs KW, McMorland GH, et al. Placental transport of metoclopramide: assessment of maternal and neonatal effects. <i>Can Anaesth Soc J</i>. 1983;30(5):487-492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/6354385/pubmed\" target=\"_blank\" id=\"6354385\">6354385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camilleri M, Parkman HP, Shafi MA, et al, &ldquo;Clinical Guideline: Management of Gastroparesis,&rdquo; <i>Am J Gastroenterol</i>, 2013, 108(1):18&ndash;37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/23147521/pubmed\" target=\"_blank\" id=\"23147521\">23147521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cersosimo RJ, Brophy MT. Hiccups with high dose dexamethasone administration: a case report. <i>Cancer</i>. 1998;82(2):412-414.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/9445200/pubmed\" target=\"_blank\" id=\"9445200\">9445200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claassen S, Z&uuml;nkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. <i>Pharmacology</i>. 2005;74(1):31-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/15640612/pubmed\" target=\"_blank\" id=\"15640612\">15640612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delpre G, Glanz I, Neeman A, Avidor I, Kadish U. New therapeutic approach in postoperative phytobezoars. <i>J Clin Gastroenterol</i>. 1984;6(3):231-237.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/6725914/pubmed\" target=\"_blank\" id=\"6725914\">6725914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiPalma JR, &ldquo;Metoclopramide: A Dopamine Receptor Antagonist,&rdquo; <i>Am Fam Physician</i>, 1990, 41(3):919-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/2407079/pubmed\" target=\"_blank\" id=\"2407079\">2407079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ellidokuz E, Kaya D. The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers. <i>Aliment Pharmacol Ther</i>. 2003;18(1):151-155.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/12848637/pubmed\" target=\"_blank\" id=\"12848637\">12848637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19708964\"></a>Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine&mdash;revised report of an EFNS task force. <i>Eur J Neurol</i>. 2009;16(9):968-981.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/19708964/pubmed\" target=\"_blank\" id=\"19708964\">19708964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman NL. Hiccups: a treatment review. <i>Pharmacotherapy</i>. 1996;16(6):986-995.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/8947969/pubmed\" target=\"_blank\" id=\"8947969\">8947969</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gan TJ, Meyer TA, Apfel CC, et al; Society for Ambulatory Anesthesia. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2007;105(6):1615-1628.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/18042859/pubmed\" target=\"_blank\" id=\"18042859\">18042859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gay&agrave; J, Barranco L, Llompart A, Reyes J, Obrador A. Persimmon bezoars: a successful combined therapy. <i>Gastrointest Endosc</i>. 2002;55(4):581-583.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/11923779/pubmed\" target=\"_blank\" id=\"11923779\">11923779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen WF, McAndrew S, Harris K, Z et al. Metoclopramide effect on breastfeeding the preterm infant: a randomized trial. <i>Obstet Gynecol</i>. 2005;105(2):383-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/15684169/pubmed\" target=\"_blank\" id=\"15684169\">15684169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ. Chemotherapy-induced nausea and vomiting. <i>N Engl J Med</i>. 2008;358(23):2482-2494.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/18525044/pubmed\" target=\"_blank\" id=\"18525044\">18525044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karadsheh NS, Shaker Q, and Ratroat B, &ldquo;Metoclopramide-induced Methemoglobinemia in a Patient With Co-Existing Deficiency of Glucose-6-Phosphate Dehydrogenase and NADH-Cytochrome b5 Reductase: Failure of Methylene Blue Treatment,&rdquo; <i>Haematologica</i>, 2001, 86(6):659-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/11418378/pubmed\" target=\"_blank\" id=\"11418378\">11418378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauppila A, Arvela P, Koivisto M, et al. Metoclopramide and breast feeding: transfer into milk and the newborn. <i>Eur J Clin Pharmacol</i>. 1983;25(6):819-823.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/6662181/pubmed\" target=\"_blank\" id=\"6662181\">6662181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, Butler HL, Lane JK, Carchman SH, Wright GJ. Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. <i>J Pediatr Gastroenterol Nutr</i>. 1988;7(6):823-829.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/3199269/pubmed\" target=\"_blank\" id=\"3199269\">3199269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, van den Anker JN, Reed MD, et al, &quot;Pharmacokinetics of Metoclopramide in Neonates,&quot; <i>J Clin Pharmacol</i>, 1998, 38(2):122-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/9549642/pubmed\" target=\"_blank\" id=\"9549642\">9549642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE, Zhao T, Wen B, Sun D. Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection. <i>Am J Health Syst Pharm</i>. 2014;71(23):2061-2065.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/25404598/pubmed\" target=\"_blank\" id=\"25404598\">25404598</a>]</span><span class=\"doi\">10.2146/ajhp130697</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kris MG, Hesketh PJ, Somerfield MR, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 [published corrections appears in <i>J Clin Oncol</i>. 2006;24(33):5341-5342]. <i>J Clin Oncol</i>. 2006;24(18):2932-2947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/16717289/pubmed\" target=\"_blank\" id=\"16717289\">16717289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Madanagopolan N. Metoclopramide in hiccup. <i>Curr Med Res Opin</i>. 1975;3(6):371-374.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/1183218/pubmed\" target=\"_blank\" id=\"1183218\">1183218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malkoff MD, Ponzillo JJ, Myles GL, Gomez CR, Cruz-Flores S. Sinus arrest after administration of intravenous metoclopramide. <i>Ann Pharmacother</i>. 1995;29(4):381-383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/7633016/pubmed\" target=\"_blank\" id=\"7633016\">7633016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mary AM and Bhupalam L, &ldquo;Metoclopramide-induced Methemoglobinemia in an Adult,&rdquo; <i>J KY Med Assoc</i>, 2000, 98(6):245-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/10870338/pubmed\" target=\"_blank\" id=\"10870338\">10870338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matok I, Gorodischer R, Koren G, et al, &ldquo;The Safety of Metoclopramide Use in the First Trimester of Pregnancy,&rdquo; <i>N Engl J Med</i>, 2009, 360(24):2528-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/19516033/pubmed\" target=\"_blank\" id=\"19516033\">19516033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCallum RW, Valenzuela G, Polepalle S, Spyker D. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. <i>J Pharmacol Exp Ther.</i> 1991;258(1):136-142.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/2072291/pubmed\" target=\"_blank\" id=\"2072291\">2072291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metoclopramide injection [product monograph]. Boucherville, QC, Canada: Sandoz Canada Inc; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metoclopramide injection [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metoclopramide oral solution [prescribing information]. Parsippany, NJ: Wockhardt USA LLC: October 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metoclopramide tablets [prescribing information]. Pulaski, TN: AvKARE Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metonia (metoclopramide) [product monograph]. Montreal, Quebec, Canada: Pendopharm; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metozolv ODT (metoclopramide) [prescribing information]. Morrisville, NC: Salix; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Middleton RS. The use of metoclopramide in the elderly. <i>Postgrad Med J</i>. 1973;49(suppl 4):90-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/4804475/pubmed\" target=\"_blank\" id=\"4804475\">4804475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27300483\"></a>Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, Tepper D. Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016 Jun;56(6):911-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/27300483/pubmed\" target=\"_blank\" id=\"27300483\">27300483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. <i>Gastroenterology</i>. 2004;127(5):1592-1622.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Protus BM, Kimbrel JM, Grauer PA. <i>Palliative Care Consultant: a reference guide for palliative care. Guidelines for effective management of symptoms</i>. 4th ed. Montgomery, AL; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quaynor H, Raeder JC. Incidence and severity of postoperative nausea and vomiting are similar after metoclopramide 20 mg and ondansetron 8 mg given by the end of laparoscopic cholecystectomies. <i>Acta Anaesthesiol Scand</i>. 2002;46(1):109-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/11903083/pubmed\" target=\"_blank\" id=\"11903083\">11903083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span><span class=\"doi\">10.1093/annonc/mdw270</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sakha K, Behbahan AG. Training for perfect breastfeeding or metoclopramide: which one can promote lactation in nursing mothers? <i>Breastfeed Med</i>. 2008;3(2):120-123.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/18564001/pubmed\" target=\"_blank\" id=\"18564001\">18564001</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seema, Patwari AK, Satyanarayana L. Relactation: an effective intervention to promote exclusive breastfeeding. <i>J Trop Pediatr</i>. 1997;43(4):213-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/9283123/pubmed\" target=\"_blank\" id=\"9283123\">9283123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siddique SM, Shariff N, Vesuwala N, Hafiz T. Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. <i>Ann Intern Med</i>. 2009;150(7):502-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/19349637/pubmed\" target=\"_blank\" id=\"19349637\">19349637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith I, Kranke P, Murat I, et al. European Society of Anaesthesiology. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. <i>Eur J Anaesthesiol</i>. 2011;28(8):556-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/21712716/pubmed\" target=\"_blank\" id=\"21712716\">21712716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&oslash;rensen HT, Nielsen GL, Christensen K, et al. Birth outcome following maternal use of metoclopramide. The Euromap study group. <i>Br J Clin Pharmacol</i>. 2000;49(3):264-268.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/10718782/pubmed\" target=\"_blank\" id=\"10718782\">10718782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stav A, Weksler N, Berman M, et al. Premedication with metoclopramide decreases the frequency of methohexital induced hiccup. <i>J Anesth</i>. 1992;6(1):17-20.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Veldhuizen PJ and Wyatt A, &ldquo;Metoclopramide-induced Sulfhemoglobinemia,&rdquo; <i>Am J Gastroenterol</i>, 1995, 90(6):1010-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/7771397/pubmed\" target=\"_blank\" id=\"7771397\">7771397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. 2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer<i>. Support Care Cancer.</i> 2017;25(1):333-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/27534961/pubmed\" target=\"_blank\" id=\"27534961\">27534961</a>]</span><span class=\"doi\">10.1007/s00520-016-3371-3</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winkler WP, Saleh J. Metoclopramide in the treatment of gastric bezoars. <i>Am J Gastroenterol</i>. 1983;78(7):403-405.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuppa AA, Sindico P, Orchi C, Carducci C, Cardiello V, Romagnoli C. Safety and efficacy of galactogogues: substances that induce, maintain and increase breast milk production. <i>J Pharm Pharm Sci</i>. 2010;13(2):162-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-drug-information/abstract-text/20816003/pubmed\" target=\"_blank\" id=\"20816003\">20816003</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9642 Version 247.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8117624\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F195600\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F195601\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F195655\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F195605\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F195630\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F195606\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F195607\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210018\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195570\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F195554\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8083407\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F195574\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F195573\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469403\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F195664\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F195561\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195578\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195558\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F195649\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195563\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195566\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F195581\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F195582\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F195568\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F195557\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F195577\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F195580\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F195583\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9642|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metoclopramide-patient-drug-information\" class=\"drug drug_patient\">Metoclopramide: Patient drug information</a></li><li><a href=\"topic.htm?path=metoclopramide-pediatric-drug-information\" class=\"drug drug_pediatric\">Metoclopramide: Pediatric drug information</a></li></ul></div></div>","javascript":null}